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Health-related quality of life in patients with prostate cancer and in their 
spouses: results from the longitudinal study 
 
Abstract  
 
Purpose: The purpose of this study was to explore changes in HRQoL (health-related quality 
of life) and identify the associated factors in patients with prostate cancer and in their spouses 
during the year following their diagnosis of prostate cancer. 
Methods: The longitudinal study design consisted of 179 patients and 166 spouses, using 
discretionary sampling, at five Finnish central hospitals. Participants completed a self-
reported RAND-36-Item Health Survey at three time-points: time of diagnosis and 6 and 12 
months later. Changes in HRQoL were analysed statistically using descriptive statistics and 
non-parametric tests. Linear mixed-effects models were used to identify the factors associated 
with the changes in HRQoL in the patients and their spouses.  
Results: On average, the HRQoL of patients with prostate cancer changes in physical 
functioning (p=0.015), emotional well-being (p=0.029) and general health (p=0.038) are 
statistically significant over the 12-month study period. In spouses, statistically significant 
changes in HRQoL were not observed. Interaction between the age of participants and change 
in HRQoL was statistically significant.  
Conclusions: Findings in this study suggest that intervention aimed at improving the HRQoL 
of patients should support a few different dimensions of HRQoL for the patients themselves 
than for their spouses. Nurses should pay more attention to elderly couples.   
 
Keywords: Longitudinal Studies, Patients with Prostate Cancer, Prostatic Neoplasms, Quality 
of Life, Spouses 
 
Highlights  
• A simultaneous follow-up of the HRQoL of these patients and their spouses is worth 
investigating.  
• Intervention aimed at improving the HRQoL of patients should support for the patients 
themselves than for their spouses.  
• Additional, nurses should pay more attention to elderly prostate cancer patients and their 
spouses.  
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Introduction 
A change such as cancer in one family member affects all family members (Wright and 
Leahey, 2012). Family members experience and react to the changed situation in different 
ways (Ervik et al., 2013). Spouses of cancer patients react strongly to the patients’ illness and 
treatment, and they experience many difficult problems and increased responsibilities during 
and after the treatment and rehabilitation phases (Gustavsson-Lilius, 2010; Ervik et al., 2013). 
Spouses provide the most important psychosocial support for patients with prostate cancer 
(O’Shaughnessy et al., 2015; Forbat et al., 2012). Prostate cancer is the most common type of 
cancer among men in developed countries as well as in Finnish men (Engholm et al., 2015; 
Ferlay et al., 2015). All treatment methods for prostate cancer are related to the distinct 
pattern of changes in quality of life (Harden et al., 2013a; Resnick et al., 2013).  
 
HRQoL is a multidimensional issue and an important patient outcome in oncology. In this 
study, HRQoL defined emotional, physical, psychological and social and functional domains 
(Aalto et al., 1999; Ware and Sherbourne, 1992). It has been stated that prostate cancer and its 
treatment options bring persistent or transient side effects, which affect the patients’ as well as 
the spouses’ quality of life (Heidenreich et al., 2011; Harden et al., 2008). Most men 
experience initial declines in HRQoL in the 2 years after treatment; there is little change from 
years 3 to 10, and most differences between treatments attenuated over time (Punnen et al., 
2015).  In a cohort study among 3294 men, surgery had the largest impact on sexual and 
urinary functions, radiation had the strongest effect on bowel function, and androgen 
deprivation therapy had the strongest effect on physical function (Punnen et al., 2015). In a 
prospective, population-based cohort study (Barocas et al., 2017), radical prostatectomy (RP) 
was associated with significant declines in sexual function compared with external beam 
radiation therapy (EBRT) and active surveillance. According to the data from a Japanese 
longitudinal study of 750 patients who underwent an RP or EBRT treatment method, the 
pattern in the changes over time of the HRQoL domains differed between the two treatment 
groups (Namiki et al., 2011). The RP group reported an improvement with regard to role 
limitations due to physical and emotional problems after an initial decline at 3 months and had 
values similar to the baseline at 24 months (Namiki et al., 2011). The EBRT group did not 
show improvements over the baseline values (Namiki et al., 2011). Compared to patients 
being managed on active surveillance (AS) and EBRT, EBRT patients reported significantly 
worse bowel function during the 3-year follow-up period (Banerji et al., 2017). In addition, 
other diseases could affect the HRQoL of prostate cancer patients. Patients’ and their spouses’ 
appraisals of the prostate cancer and their dyadic communication were associated with their 
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long-term QoL (Song et al., 2016). Ross and colleagues (2016) examined that not only 
patients but also their spouses experience a significant decrease in mental and physical health 
1 month post surgery.  
 
Associations between socioeconomic status (SES) and HRQoL among patients with prostate 
cancer are identified in a German longitudinal prospective cohort study (Klein et al., 2016). 
Lower SES as income, education and employment status was significantly associated with 
lower HRQoL 6 months after radical prostatectomy treatment (Klein et al., 2016). A previous 
study has shown that prostate cancer survivors with comorbid diabetes have poorer cancer-
specific and general HRQoL than those without diabetes (Thong et al., 2011).  
 
Several studies have identified the associations between treatment methods and the HRQoL of 
patients with prostate cancer or their spouses (Vasarainen et al., 2013; Harden et al., 2013b). 
Although, there is some knowledge about HRQoL in patients with prostate cancer, a 
simultaneous follow-up on the HRQoL of these patients and their spouses is worth 
investigating further. 
 
Aims 
The aim of this study was to explore changes in HRQoL and identify the associated factors in 
patients with prostate cancer and their spouses during the year following their diagnosis of 
prostate cancer. The research questions were: 
1. How does the HRQoL of patients with prostate cancer and their spouses change during 
the year following their diagnosis of prostate cancer?  
 
2. Which factors are associated with changes in the HRQoL of patients with prostate 
cancer and their spouses during the 1-year follow-up period?  
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Methods 
Sample, study design and participants  
The data for this longitudinal study consisted of patients with prostate cancer (N=350) and 
their spouses (N=350), using discretionary sampling at the time of diagnosis and during the 1-
year period that followed. The study design was approved by the Scientific Committee of the 
local hospital district. The directors of the 5 participating hospitals permitted its execution. 
Each participant was informed orally and in writing about the purpose of the study and of the 
principle of voluntary, anonymous participation. 
 
The sample size was based on previous studies (Osoba et al., 2005) and was calculated 
together with a statistician. A clinically significant change in HRQoL scores was determined 
on a 10-point scale. The sample size calculation was based on a paired-samples t test. Using a 
standard deviation of 20 with an alpha value of 0.05 and a power of 0.8, a change of 10 points 
was calculated to be statistically significant with a sample of 33 participants (Osoba et al., 
2005). Because there were 3 points of measurement, 5 different hospitals and at least 4 types 
of treatment, the questionnaire was distributed to 350 couples at the first measurement point.  
 
In the first stage of this study, the participants were recruited between October 2013 and 
January 2016 from the outpatient urology clinics of five Finnish central hospitals. The 
inclusion criteria were (i) patients examined with prostate cancer who were at the pre-
treatment stage, (ii) patients that characterised their relationship with their spouse as 
permanent, and (iii) patients who provided written informed consent and additional contact 
information for their spouses. 
 
At the 6-month post-diagnosis data collection point, there were 199 of 231 (86%) patients 
with prostate cancer and 195 of 228 (86%) spouses. The questionnaires were sent to patients 
or spouses who had answered the questionnaire at the time of diagnosis and were willing to 
continue with the study. At the second stage, data collection was carried out between April 
2014 and July 2016.  
 
At the third stage, 1-year post diagnosis, the response rate was 90% (n=179) for the patients 
and 85% (n=166) for the spouses. The main analyses employed all participants with available 
data at each of the 3 time-points (patients n=179, spouses n=166). 
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During the period under investigation, the patients had four different treatment method 
options: Surgery (all forms of radical prostatectomy), radiation therapy (brachytherapy and 
external beam radiation), hormonal treatment, and non-invasive care (active and passive 
follow-up care).  Treatment protocols for prostate cancer did not differ between the five 
hospitals, but nursing appointments did vary between the hospitals. 
 
 
Data collection methods 
General HRQoL was assessed using the RAND-36-item health survey (RAND-36), which 
included 8 health dimensions: physical functioning, role functioning/physical, role 
functioning/emotional, energy, emotional well-being, social functioning, bodily pain and 
general health (Aalto et al., 1999; Ware and Sherbourne, 1992). The RAND-36 is a widely 
used measure of generic HRQoL. The subscales were linearly converted to a 0−100 scale 
according to standard scoring procedures, with higher scores indicating a better HRQoL 
(Aalto et al., 1999). For the RAND-36, differences of ≥ 10 points were considered clinically 
meaningful (Osoba et al., 2005). The RAND-36 has been validated for the Finnish population 
(Aalto et al., 1999). 
 
The demographic variables included age, duration of the marital relationship, education 
status, employment status, other diseases, place of treatment and treatment methods. 
 
Data analysis 
Data were described using frequencies, percentages, means and standard deviations. Changes 
between the time of diagnosis and 1 year after diagnosis were analysed using the Wilcoxon 
signed-rank test due to skewed distributions. Calculations were performed using the IBM 
SPSS statistics Version 23 (IBM Corp., Armonk, NY, USA) and R version 3.3.0. Linear 
mixed-effects models using the function ‘lme’ were assessed for all eight health dimensions 
separately for prostate cancer patients and their spouses. Age, duration of the marital 
relationship, education status, employment status, other diseases, place of treatment and 
treatment methods were used as independent variables, together with time-variable (three time 
points), with patient models. For spouses’ models, place of treatment and treatment methods 
were not used. A random intercept for individuals with a random slope for individual time 
variations were used together with independent random errors. The level of statistical 
significance was set at p < 0.05 (Munro, 2005). 
  
  
7 
 
Results 
Demographic characteristics of participants 
Responses were received from 179 (51%) patients and 166 (47%) spouses 1 year after 
diagnosis. The mean age of the patients was 68 years (9.78) and of the spouses 66 years 
(8.67). The demographic characteristics of participants are presented in Table 1.  
 
 
HRQoL during the 1-year follow-up 
Table 2 summarises HRQoL during the year following prostate cancer diagnosis. On average, 
the HRQoL of the patients with prostate cancer change in physical functioning, emotional 
well-being and general health was statistically significant over the 12-month study period. 
The mean of physical functioning of the patients was M 81.0 (SD 21.4) at the time of 
diagnosis and M 79.2 (SD 21.1) 12 months after. The difference was statistically significant 
(p=0.015). For emotional well-being, the change went from M 75.6 (SD 16.3) to M 78.9 (SD 
15.7) (p=0.029), and for general health, it went from M 58.7 (Sd 17.8) to M 58.3 (SD 21.1). 
In patients, there were no other statistically significant changes. In spouses, statistically 
significant changes in HRQoL were not observed. In addition, Table 2 includes data for 
participants for whom the HRQoL changed by 10 points or more on the RAND-36 scale. 
Patients’ and spouses’ changes were very similar. 
 
Factors associated with change in HRQoL 
Linear mixed-effects models were used to explore the demographic variables regarding 8 
dimensions of HRQoL. HRQoL was a dependent variable and the demographic variables 
together with time were independent variables.  
 
Linear mixed-effects modelling showed that changes in the HRQoL of participants were 
minor over the 12-month study period. Clinically significant changes in HRQoL were not 
observed. On average, general health decreased 2 points on the RAND-36 scale.  
 
The effect of demographic variables was insignificant. Twelve months after prostate cancer 
was diagnosed, the demographic variables did not significantly explain the variance of the 
participants’ HRQoL. Only the interaction between the participants’ ages and changes in their 
HRQoL was statistically significant in some of the models. The HRQoL of participants over 
the age of 70 decreased more than in the younger participants.  
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Discussion 
This study reported changes in the HRQoL of patients with prostate cancer and their spouses 
at the 1-year follow-up period. The main findings were that the HRQoL of the patients and 
their spouses changed during the follow-up period. Physical functioning and general health of 
patients decreased, and emotional well-being of patients increased. Similar changes were not 
observed in spouses, as they did not have statistically significant changes in HRQoL 
dimensions.  
 
These findings support the previous studies, which concluded that patients with locally 
advanced or advanced prostate cancer reported decrements, especially in physical quality of 
life at 2, 6, 12, 24 and 48 months after their diagnoses (Zajdlewicz et al., 2017), and the QoL 
of spouses was generally good based on a generic QoL instrument in a longitudinal 2-year 
follow-up study (Harden et al., 2013a). Similarly, another longitudinal study of men with 
advanced prostate cancer reported that HRQoL fluctuates from the time of diagnosis to 5 
years after, but a substantial proportion of the men remained distressed (Zajdlewicz et al., 
2017). According to Paterson et al. (2015), a significant decline in quality of life was 
observed at 6 months post diagnosis when they used a prostate cancer–specific measurement. 
Correspondingly, most men experience initial declines in HRQoL in the 2 years following 
their treatment; there is little change in years 3 to 10, and most differences between treatments 
attenuated over time (Punnen et al., 2015). On the other hand, a Spanish study in patients with 
lung, head, neck, colorectal, or breast cancer reported that after 3 months of usual care, there 
was a significant improvement in pain and the quality of life (Maximiano et al., 2018). Our 
findings show that clinically significant changes in HRQoL were not found in this study. Our 
results add important knowledge about understanding the family dynamics of men with 
prostate cancer. 
 
A surprising finding in this study was that the emotional well-being of patients increased 
during the follow-up period. This could be because after the prostate cancer diagnosis, 
patients are able to better share their concerns with their spouses or healthcare professionals 
when their emotional well-being has increased. According to Ernstmann et al. (2017), patient-
provider communication is a valuable resource to support patients with prostate cancer. This 
study thus supports the recommendations of Ernstmann et al. (2017) that interventions, 
especially for urologists, enhance their awareness about the importance of communication and 
their relationships with their patients for treatment outcomes. On the other hand, previous 
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studies (Gustavsson-Lilius, 2010; Lim et al., 2015) showed that male patients with cancer 
tended not to talk about their negative symptoms with their spouses. 
 
Our discovery regarding the ages of patients and their spouses and how they affect changes in 
general health are in agreement with previous studies (Song, Northouse et al., 2011; 
Harrington, Schwenke et al., 2013) and suggest potential intervention targets. Prior study 
suggests nurses pay more attention to couples older than 70 years who have other chronic 
disease or who receive hormonal treatment (Harju et al., 2017). Otherwise, previous studies 
have shown that a younger age was associated with a poorer QoL (Harden et al., 2008; Wu 
and Harden, 2015). However, it should be noted that in our study, the interaction of 
demographic variables with the changes of HRQoL was not found. One explanation for this 
could be that the follow-up period is too short. However, the longitudinal study is to our 
advantage. The strength of this study is that the data are longitudinally and simultaneously 
collected from the same patients with prostate cancer and their spouses. 
 
Limitations 
This study has several limitations, which should be noted when considering the findings. 
First, this study focused on patients with prostate cancer who live in a marital relationship. 
Second, the use of only one scale of HRQoL (RAND-36) could simplify the complex concept 
of QoL. Third, there may have been selection bias in the data collection. The respondents who 
were willing to participate in this study were mostly likely those who were healthy. 
Furthermore, some respondents may have overemphasised their poor health to elicit 
sympathy. Last, self-reported data on early disease and treatment methods are limited by the 
patients’ understanding and recall of treatments. To improve reliability, information on 
chronic diseases and the progression of prostate cancer could be collected from medical 
records. Confounders, such as support groups, or family relationships, or economic factors, 
may also have influenced the results. 
  
In conclusion, 1 year after prostate cancer diagnosis, changes in physical functioning, 
emotional well-being and general health are common in patients, but not in spouses. The only 
significant factor for changes in one dimension of HRQoL was age. To improve HRQoL in 
patients with prostate cancer, this study highlights the need to target support for the physical 
functioning of patients and older couples. 
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Table 1. Demographic characteristics of patients with prostate cancer (n=179) and their 
spouses (n=166) one year after diagnosis  
 Patients Spouses 
Variable n % n % 
One-year follow-up 
Age (years) 
≤ 59  
60–69  
≥ 70  
 
 67.9(9.8) ͣ 
30 
70 
79 
 
 
17 
39 
44 
 
 65.6(8.7) ͣ 
40 
68 
58 
 
 
24 
41 
35 
Duration of marital relationship (years) 
≤ 25  
26–40  
≥ 41  
 36.0(15.6) ͣ 
48 
43 
88 
 
27 
24 
49 
  
Basic education 
Elementary school/civic school 
Comprehensive school/lower 
secondary school 
Upper secondary school 
 
101 
48 
30 
 
 
56 
27 
17 
 
 
72 
45 
49 
 
 
43 
27 
30 
 
Employment status 
Working 
Not working 
 
57 
122 
 
32 
68 
 
67 
99 
 
40 
60 
Chronic diseases 
Yes 
No 
Missing 
 
127 
51 
1 
 
71 
29 
 
106 
60 
 
64 
36 
Treatment method 
Radiation therapy 
Surgery 
Non-invasive care 
Hormonal treatment 
Missing 
 
65 
63 
32 
18 
1 
 
37 
35 
18 
10 
 
  
 
ͣ =mean (standard deviation)
  
14 
 
Table 2. Changes in participants’ health-related quality of life (RAND-36) 
Quality of life dimension  At the time of 
diagnosis (baseline) 
After 12 months (follow-
up) 
Change p value 
for the 
differenc
e 
between 
the 
baseline 
and 
follow-
up² 
 
HRQoL 
increased by 
≥10 points 
 
HRQoL 
decreased 
by ≥10 
points 
  M¹ 
n=205 
SD M¹ 
n=177 
SD M SD    
n 
%  n % 
Physical functioning Patients 
Spouses 
n=194, 81.0 
n=214, 79.1 
21.4 
20.1 
n=177, 79.8 
n=166, 78.5 
21.1 
21.9 
n=166, -2.5 
n=149, -2.4 
15.6 
10.7 
0.015 
0.540 
26 
16 
16 
11 
46 
37 
28 
25 
Role functioning/physical Patients 
Spouses 
n=215, 65.8 
n=213, 70.2 
40.7 
38.0 
n=177, 65.4 
n=166, 67.9 
42.3 
38.1 
n=165, -0.2 
n=149, -4.2 
36.6 
27.0 
0.889 
0.589 
32 
25 
19 
17 
38 
40 
23 
27 
Role functioning/emotional Patients 
Spouses 
n=216, 70.4 
n=213, 73.7 
38.7 
36.3 
n=176, 72.9 
n=165, 74.9 
37.1 
36.9 
n=166, -0.4 
n=149, -2.0 
38.1 
34.3 
0.979 
0.411 
33 
28 
20 
19 
39 
31 
23 
21 
Energy Patients 
Spouses 
n=216, 67.3 
n=214, 67.9 
21.0 
18.2 
n=177, 68.3 
n=165, 66.7 
20.4 
19.4 
n=166, -0.1 
n=149, -0.9 
17.9 
14.5 
0.745 
0.331 
47 
39 
28 
26 
48 
43 
29 
29 
Emotional well-being  Patients 
Spouses 
n=216, 75.6 
n=214, 75.5 
16.3 
15.1 
n=177, 78.9 
n=166, 76.7 
15.7 
17.1 
n=166, 2.5 
n=149, 1.3 
15.7 
14.4 
0.029 
0.156 
40 
38 
24 
26 
25 
28 
15 
19 
Social functioning Patients 
Spouses 
n=217, 82.3 
n=214, 84.6 
22.3 
18.1 
n=178, 83.8 
n=166, 84.4 
20.0 
19.6 
n=168, -0.1 
n=149, -1.5 
22.6 
18.0 
0.706 
0.441 
55 
38 
33 
26 
50 
44 
30 
30 
Bodily pain Patients 
Spouses 
n=217, 75.6 
n=213, 74.0 
23.2 
23.0 
n=178, 75.5 
n=166, 72.1 
24.0 
24.1 
n=168, -0.2 
n=149, -2.4 
20.7 
18.3 
0.522 
0.119 
52 
37 
31 
25 
58 
65 
35 
44 
General health Patients 
Spouses 
n=217, 58.7 
n=213, 61.3 
17.8 
17.5 
n=177, 58.3 
n=165, 60.8 
21.1 
20.4 
n=167, -2.5 
n=149, -1.4 
14.0 
12.5 
0.038 
0.099 
44 
35 
26 
23 
65 
50 
39 
34 
¹Scale: 0: poor health and quality of life; 100: good health and quality of life 
²Wilcoxon signed-rank test 
 
